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Abstract
Current cardiovascular stent platforms interact poorly with the human vasculature and still rely on drug therapy to avoid early failure due to blood
clotting. A drug-free coating technology that could fully integrate an implanted stent through a combination of hemocompatibility and differential regulation
of endothelial cells and smooth muscle cells would present a clear advantage over existing clinical approaches. Plasma discharges have been used as a
coating technology in a wide range of applications over the last decades. Carbon-based thin ﬁlms prepared by different plasma deposition methods are
usually regarded as biocompatible materials as they are able to prevent the adhesion and activation of platelets and preferentially promote the adsorption of
albumin over ﬁbrinogen. However, the available literature seldom addresses entirely the aspects of biocompatibility and the challenging mechanical
demands of such materials for stent coating. Recent advances suggest that plasma enhanced chemical vapour deposition can be used to prepare carbon-
based thin ﬁlms that allow for the linker-free immobilization of bioactive molecules. If successfully applied to a stent these coatings could represent a step
towards stent speciﬁc biofunctionalization. This review examines the feasibility of using plasma discharges for the synthesis of carbon-based biocompatible
materials for cardiovascular implantable devices, particularly stents.
& 2015 Southwest Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Every year more than 6 million people undergo surgery
around the world for the insertion of medical implants such as
hip and knees prostheses, pacemakers, heart valves and coronary
stents [1,2]. In the US alone around 1 million orthopaedic
implants are inserted annually for knee and hip replacements [3]
and these numbers are expected to rapidly increase to around 3
million by the year 2030 [4]. The increasing life expectancy of
the population elevates demands for medical implants with a
superior life span that can resist corrosion and wear, especially in
load bearing and blood and/or tissue contacting applications.
Additionally, insertion of exogenous materials into the body
triggers immune responses in the areas surrounding the implant
which can compromise implant performance and even necessi-
tate revision surgery for implant replacement or extraction.
Novel surface technologies that could mediate interactions
between the implant and the host to prevent adverse reactions
would clearly beneﬁt the biomedical devices industry. In
particular, there is a great demand for a universal technology
capable of producing tailored biofunctional interfaces to simul-
taneously address a number of speciﬁc tasks depending on the
application. Modulation of the surface properties such as
hemocompatibility, protein adsorption / immobilization, differ-
ential attachment, proliferation and differentiation of cells are
highly desirable. This review investigates the potential of using
plasma-based tools as a universal coating technology for
implantable medical devices, with particular focus on coronary
stents. The deposition of biofunctional surfaces on coronary
stents is a particularly interesting and complex case study as it
combines: (i) physical–chemical, (ii) mechanical, (iii) geometric,
(iv) blood clotting and (v) cellular response considerations.1.1. Current coronary stent platforms
The World Health Organization [5] estimates that cardiovascular
diseases represent 30% of total deaths worldwide, with coronary
heart complications, including atherosclerosis, leading the list with
a total of 7.3 million deaths every year. The same organization
predicts that these numbers will rise up to 8% within the next 15
years, exacerbating an already serious problem. In the last three
decades, percutaneous coronary interventions became widely used
in the treatment of cardiovascular diseases and have been
established as the ﬁrst-line technique for revascularization of the
coronary arteries. Among implantable biomedical devices, coron-
ary stents are now the dominant vascular implant in percutaneous
coronary interventions [6] with around 800,000 stents implanted
annually in the US alone [7]. Stents are expandable cylindrical
meshes used to re-establish the normal blood ﬂow in blocked
atherosclerotic coronary arteries, resupplying ischemic tissue.However, despite their widespread use, current stent platforms
have only sub-optimal biocompatibility, interacting poorly with
vascular cells and promoting blood clot formation.
The ﬁrst commercially available stent platform was based on
metallic alloys such as stainless steel (SS). Despite the extra-
ordinary results in reducing the rate of abrupt vessel closure, one
of the major pitfalls of coronary angioplasty, post-procedure
complications related to stent implantation started to arise. The
most common was in-stent restenosis, triggered by an inﬂam-
matory response due to blood vessel intima injury during stent
deployment. Damage to the endothelium led to the migration and
over-proliferation of underlying smooth muscle cells (SMC),
causing vessel re-narrowing in a process called neointimal
hyperplasia [8]. In order to overcome the draw-backs of bare
metal stents, drug eluting stents (DES) were introduced. DESs
are grafted with layers of biodegradable [9–11] or non-
biodegradable [12–14] polymers, in which a pharmacological
agent is loaded and can be locally released within a given period
of time. By incorporating anti-proliferative agents, drug-eluting
stents were successful in inhibiting the over-proliferation of
SMC, hence reducing the effects of hyperplasia. However, an
unintended consequence of DES was a substantially increased
risk of long-term stent thrombosis, termed late stent thrombosis
(LST) [15]. LST is mainly associated with reduced re-
endothelialisation of the stent, leading to a delayed healing of
the vessel and over-exposure of the stent struts to the blood.
Another possible reason for late thrombosis could be associated
with adverse inﬂammatory responses to the drugs and the grafted
polymer used in these stents. Extensive research has been
undertaken to address the issues of in-stent restenosis and late-
stent thrombosis, either through the development of more
biocompatible polymer-based coatings [16,17] or by integrating
speciﬁc antibodies with the ability to recruit and immobilize
endothelial progenitor cells [18–20], thus promoting re-
endothelialisation. The incorporation of nitric oxide (NO) donors
in the stent design has also been considered as an encouraging
alternative platform to reduce in-stent restenosis and LST. NO is
an endogenous signalling molecule that participates in important
biological processes and possesses several vasculoprotective
properties [21]. It has been shown that the administration of
different NO donors inhibits the proliferation and migration of
SMC [22,23], enhances the proliferation of endothelial cells [24],
prevents platelet aggregation [25] and adhesion [26] to the
vascular endothelium and reduces intimal hyperplasia following
vascular injury [27]. The delivery of NO through eluting stent
platforms has been achieved by incorporating NO donors in a
polyurethane polymer which was then coated onto the stents [28]
or by incorporating the NO donor with paclitaxel [29] (an anti-
proliferative agent extensively used in the prevention of rest-
enosis). However, no signiﬁcant improvements in preventing
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in-vivo animal trials.
A new generation of bioabsorbable stents [30–32] have been
prompting increasing interest from the scientiﬁc community. In
theory, these stents can be temporarily used has a treatment for
atherosclerosis as they are dissolved in the body after a period
of time, leaving behind a structurally normal and recovered
blood vessel. Although promising, some issues regarding their
mechanical properties, which are paramount for a proper stent
deployment, radio-opacity and control over the rate that they
are absorbed in the body still need to be addressed [33].
Currently used DES platforms still carry an ongoing risk of
thrombosis requiring patients to be on pharmacological dual anti-
platelet therapies, which can result in bleeding and is not feasible
for patients requiring additional surgery. A drug-free coating
technology, with all the necessary mechanical and biological
properties for enhancement of the clinical performance of
coronary stents, would provide a clear beneﬁt over current stent
platforms. In particular, the coating should be able to resist
cracking and delamination during and after stent deployment in
order to avoid the contact of the struts with the blood stream. It
should also be multi-functional, promoting the adhesion and
proliferation of endothelial progenitor cells, for re-endothelialisa-
tion, while also inhibiting the over-proliferation of smooth
muscle cells to avoid hyperplasia.
1.2. Plasma activated biofunctional stents
Waterhouse et al. [34] reported the feasibility and safety of
delivering a prototype plasma-activated coating (PAC) in vivo.
This coating was deposited using hydrocarbon-based radio-
frequency plasma discharges and prepared with energetic ions
and a graded interface between the stainless steel surface and
the PAC coating to provide sufﬁcient adhesion. Following
some initial optimisation of mechanical and biological proper-
ties the coating was applied to a stent and implanted in rabbit
iliac arteries. Results showed that PAC had sufﬁcient adhesion,
undergoing stent crimping and expansion, and performed
equivalently in terms of re-endothelialisation when compared
to bare metal stent platforms.
Plasma discharges have been extensively used as a coating
technology in a vast number of applications. The extreme
versatility of plasma-based systems could be fostered to provide
a universal coating platform for biocompatible and multi-
functional cardiovascular implants. A considerable number of
publications have reported the viability of using plasma-based
technologies for the manufacture of biofunctional coatings for
cardiovascular implants. These works were recently reviewed by
Wise et al. [35]. Efforts have been made to deliver mechanically
robust coatings with sufﬁcient adhesion strength to metallic
substrates. Wear and corrosion resistance due to ﬂuid permeation
after prolonged exposures to body ﬂuids has also been a concern.
With regards to coating biocompatibility, it is still not clear
which physical and/or chemical properties play the most
important roles. Bonding conﬁguration, chemical composition,
presence of dopants, surface roughness and wettability have been
regarded has important factors predominantly affecting bloodprotein adsorption and cellular response such as platelet adhesion
and activation.
Previous studies [36,37], also showed that carbon-based
polymer-like coatings produced by plasma-enhanced chemical
vapour deposition (PECVD) with enhanced ion-bombardment
possess superior biological qualities over conventional coating
alternatives (e.g. chemical vapour deposition, physical vapour
deposition and wet techniques such as solvent dipping).
Importantly, these coatings also allow the covalent immobili-
zation of biomolecules [38]. The possibility to conjugate
bioactive molecules to biomedical implants is particularly
interesting. The development of more biocompatible stents
may be achievable through a speciﬁc and controlled functio-
nalization via the stable immobilization of bioactive proteins or
peptides that can interact with the vasculature, especially by
promoting endothelialisation, inhibiting the proliferation of
smooth muscle cells and reducing the formation of thrombus.
2. Plasma synthesised carbon-based coatings
Among the four fundamental states of matter, (i.e. solid,
liquid, gaseous and plasma), plasma is the most abundant in
the Universe. For instance, the stars, interstellar and inter-
galactic space, nebulae, lightning and auroras borealis are all in
the form of plasma. The plasma state is achieved when enough
energy is supplied to a gas, or a gaseous mixture, so that a
fraction of the atoms (or molecules) that constitutes that
medium becomes ionised. In contrast to a gaseous medium,
formed only by non-charged species (atoms and/or molecules),
the plasma medium is comprised not only of non-charged but
also by charged species (ions and electrons) and photons.
Therefore, the electrical and thermodynamical properties
inherent to a plasma medium are far more complex and subtle
than in the gaseous state. The complex interaction between
positively and negatively charged particles gives rise to
complex phenomena and collective behaviours, which are
unique to the plasma and may vary depending on the
conditions in which the plasma is produced and sustained.
Plasmas can also be produced in laboratory conditions.
Humankind has been studying and developing different ways
to produce and control plasmas for its own beneﬁt for more
than 130 years. Plasma discharges have found a large number
of applications from illumination, metallurgy, micro-electro-
nics, environment, materials engineering, analytical spectro-
scopy, medicine, etc [39]. The success of man-made plasma
discharges is a result of the unique physical and chemical
characteristics inherent to this medium, as well as the extra-
ordinary ﬂexibility achieved so far in controlling a large
window of working conditions. Plasma can be artiﬁcially
produced in a wide range of size scales (from micrometre up
to several metres), geometries (planar, cylindrical, spherical,
etc.), densities (from 107 up to 1032 particles per cubic meter),
pressures (from a few mTorr up to atmospheric pressure),
temperatures (from negative values up to 108 1C) and lifetimes
(from femtoseconds up to years).
Depending on the type of application, many different
techniques of plasma generation can be used. For instance,
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desirable to achieve high levels of purity in the coatings.
The use of a vacuum chamber, where the system is pumped
down to very low pressures, allows control of the plasma
composition and, therefore, also the coating composition.
Magnetic ﬁelds and high voltage sources can also be used to
gain control over trajectory and energy of the charged species
that reach the surfaces to be coated. In the last decades for
instance, different types of plasma discharges have proven
their potential for biomedical applications, for a wide range of
tasks such as sterilisation, cell proliferation, treatment of oral
pathogens and healing of burn wounds [40]. Low pressure and
low temperature plasmas have become widely used for surface
modiﬁcation in different applications, including the deposition
of thin-ﬁlms on implantable biomedical devices. Organosilicon
and hydrocarbon precursors are commonly used for the
creation of hydrogenated silicon ﬁlms and amorphous hydro-
genated carbon ﬁlms (frequently named diamond-like carbon
ﬁlms) for a wide range of applications. The rich composition
of the plasma medium, i.e., electrons, ions, atoms, radicals,
molecules and photons, is achieved through efﬁcient dissocia-
tion and ionization of precursor and carrier gas atoms and
molecules, which takes place via many different kinetic
mechanisms and energy transfer channels. The resulting
precursor ions and radicals then diffuse towards the substrate,
initiating a set of surface chemical reactions and ultimately
leading to the deposition and growth of a coating on the
substrate surface.
PECVD, for instance, is a popular and extremely versatile
plasma-based technology for the deposition of thin ﬁlms [41].
The plasma is generated at low temperatures (typically ambient
temperature) inside a vacuum chamber and is typically
sustained by capacitively coupling radio-frequency (rf) power,
usually at a frequency of 13.56 MHz, through a matching
network so as to minimise power losses within the external
electrical circuit. The rf power can be coupled to the plasma
either in continuous or in pulsed regimes [42]. A pulsed power
modulation regime is frequently used in plasma polymerization
representing an extra degree of freedom in the deposition
process. Samples can also be electrically biased to accelerate
the plasma ions towards the growing ﬁlm. The applied bias can
be either continuous DC [43], radio-frequency [44] or pulsed
[45]. Control over the chemical composition of the coatings is
achieved by choosing different gases (or gaseous mixtures) to
generate the plasma. The coatings deposited by PECVD,
especially when bias is used to increase the energy of the
depositing species, are characterised by superior adhesion to
the substrates, high cross-linking, improved biocompatibility
and chemically active and functional surfaces. This deposition
technology also allows a level of control over different
properties of the ﬁlms, such as roughness, wettability, hard-
ness, density, ﬂexibility and composition without changing the
properties of the underlying substrate. This control is achieved
by tuning the different process parameters—a difﬁcult task
given the complexity of the plasma and the use of reactive
gaseous mixtures. Therefore, the process optimization for the
deposition of thin-ﬁlms with desired features is time-consuming and requires further characterization and under-
standing of the plasma medium.
It is paramount, therefore, to understand how changes in the
process parameters, e.g. power coupled to the plasma, pres-
sure, temperature, sample bias and different gas ratios affect
the plasma physical quantities and how sensitive the coating
properties are to those. Process monitoring via different plasma
diagnostic techniques using electrostatic probes [46], optical
emission spectroscopy (OES) [47] and mass spectroscopy [48]
can ultimately assist in modulating key features in the ﬁnal
coating. For instance, the radiation emitted by the plasma due
to electronic, vibrational and rotational atomic and molecular
transitions can be analysed by means of OES and infrared
spectroscopy. The plasma optical signature retains pertinent
information about the most populated atomic and molecular
states within the plasma. Such information can be used to
derive the relevant channels of creation and destruction of
those populations. Electron and ion temperature, density and
their transport in the discharge can also be understood through
electrical diagnostics, using for instance Langmuir probes and
quadrupole mass spectrometers. The electron energy distribu-
tion function (EEDF) can also be obtained using the former
diagnostics. Important macroscopic parameters can be deter-
mined by appropriate integrations of the EEDF [49] in energy
space. These include, for instance, electron mobility, diffusion
coefﬁcients, drift velocity, characteristic energy, power
absorbed by the plasma, plasma conductivity and all the
excitation / de-excitation, dissociation and ionization coefﬁ-
cients related with the plasma kinetic mechanisms involving
collisions between electrons and other populations. There is
also a great demand for simulation models capable of describ-
ing such discharges and their operation. Plasma self-consistent
modelling with the necessary complexity to describe the main
plasma kinetic mechanisms, the transport of species and
plasma / surface interactions are seldom available. Complex
hybrid simulation tools [50] comprising state-of-the-art colli-
sional–radiative models [51], plasma ﬂuid models [52] and
plasma / surface interactions could be developed to address
fundamental investigations, reactor design and optimization to
ultimately provide stabilization and reproducibility of the
fabrication process. Research combining plasma modelling,
plasma experimental diagnostics and coating characterization
techniques will yield further important insights on how
discharge parameters affect the coating properties.
2.1. Diamond-like amorphous carbon and polymer-like
carbon-based thin ﬁlms
The exceptional physical, chemical and tribology properties
of plasma synthesised diamond-like carbon (DLC) have
prompted an increasing volume of research since they were
ﬁrst synthesized in the form of thin ﬁlms in 1971 [53]. The
potential use of DLC as a biocompatible coating for medical
implants in a wide range of applications has been extensively
investigated in the last 2 decades. A considerable number of
review papers covering these investigations are now available
[54–58]. The use of DLC coating for orthopaedic prostheses
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guiding wires and coronary stents [61] are among the most
common examples.
The designation DLC is commonly attributed to a variety of
amorphous carbon-based materials that may contain different
sp2 and sp3 carbon bond ratios as well as different hydrogen
contents. Depending on the bonding conﬁguration and the
hydrogen content, DLC materials are usually sub-classiﬁed
into: (i) tetrahedral amorphous carbon (ta-C) for higher sp3
contents (typically 470%) and low levels of hydrogen; (ii)
amorphous carbon (a-C) if the ratio sp3/sp2 ranges between 0.4
and 0.7 and (iii) hydrogenated amorphous carbon (a-C:H) for
hydrogen containing materials which are typically charac-
terised by higher sp3/sp2 ratios but they are soft because many
of the sp3 bonds are hydrogen terminated. The properties of
DLC thin ﬁlms, their mechanisms of deposition and their
characterization techniques were extensively reviewed by
Robertson [62] and McKenzie [63].
Highly hydrogenated soft a-C:H thin ﬁlms are usually
denominated by hydrocarbon plasma polymers [64–66]. These
ﬁlms are characterised by a polymer-like structure which is
deposited on the substrate material. The atomic arrangement of
this structure is strictly dependent on the type of carbon
precursor (monomer) and the process parameters used during
the deposition. Carbon-based polymer-like deposits are usually
highly cross-linked and may contain large concentrations of
imprisoned radicals. The mechanisms of plasma polymeriza-
tion are still not fully understood and several models have been
proposed in the last decades and these were also recently
reviewed [67].
Carbon-based materials can be prepared as a coating in the
form of a ﬁlm using a wide range of plasma-based deposition
techniques. Different properties of the DLC and polymer-like
carbon coatings can be tuned by setting adequate deposition
parameters. For instance, ta-C thin-ﬁlms prepared by arc
vapour deposition [68,69] are characterised by extreme hard-
ness (up to 80 GPa), great wear and corrosion resistance and
chemical inertness. These properties make ta-C potential
coating candidates for load-bearing biomedical applications
[70]. However, the high internal compressive stress character-
istic of thick ta-C ﬁlms still remains the primary source of
coating failure in orthopaedic implants [69]. The exposure of
the underlying metallic substrate due to poor adhesion and
delamination presents one of the major obstacles to the
commercial success of DLC coatings.
a-C ﬁlms can be prepared using a variety of plasma-based
deposition technologies. For instance, a-C materials are usually
made by plasma magnetron sputtering (PMS) where a graphite
target is exposed to argon plasma [71,72]. Carbon atoms and
ions are sputtered from the graphite target and are then deposited
onto the substrates. Substrates to be coated are usually electri-
cally biased [73] which allows control over the kinetic energy of
the carbon ions reaching the samples. Control over the bias
voltage is characteristically used to deliver ﬁlms with different
physical structures, surface topographies and sp3/sp2 ratios.
a-C:H are commonly prepared by PMS [74–76] or by plasma
enhanced plasma vapour deposition (PECVD) [77,78]. In theﬁrst case, a reactive mixture of argon and hydrogen is injected in
the PMS reactor. Hydrogen atoms bind with the sputtered carbon
atoms leading to the deposition and growth of a hydrogenated
carbon thin ﬁlm. The concentration of hydrogen gas during the
deposition process can also be adjusted to yield ﬁlms with
different hydrogen contents, hence with diverse properties as
well. Highly hydrogenated a-C:H have reduced internal stress
[55] resulting in improved ﬁlm adhesion to the underlying
substrates [79]. Hydrogen also behaves as an etching element
and increasing the hydrogen concentration in the plasma was
reported to promote surface smoothness of the ﬁlms [62].
Control over the chemical composition of the DLC coating by
PECVD is achieved by choosing different gases, or gaseous
mixtures, to generate the plasma. While argon is commonly used
as the background gas, different hydrocarbon precursors (acet-
ylene, methane, ethylene, ethane, butane, etc.) are used to tailor
different chemical and physical structures of the a-C:H ﬁlms. For
instance, increased hydrogen contents and smoother surfaces can
be created by using methane (CH4) instead of acetylene (C2H2)
as the precursor gas [80]. Also, the incorporation of hydrogen in
CH4 plasmas was shown to reduce the coating friction and wear
when deposited on steel substrates [81]. The incorporation of
dopants, such as nitrogen, phosphorous, ﬂuorine or silicon can
also be easily performed by choosing the appropriate gaseous
mixture. This feature is particularly interesting since the combi-
nation of these elements with DLC was shown to be paramount
in tailoring the mechanical and biological performance of the a-
C:H coatings. It is now generally accepted that sample bias is a
fundamental process parameter in the production of DLC coat-
ings. Films with variable sp3 fraction[82], residual stress [83],
substrate adhesion [84], refractive index [85] and hemocompat-
ibility [86] can be prepared by adjusting solely the sample bias
while maintaining constant the other process parameters. Impor-
tantly, sample bias promotes the creation of radicals in the
coating’s surface and bulk, allowing for a further functionaliza-
tion of the coated materials with bioactive proteins, peptides and
other biomolecules [36].2.2. Improving the mechanical stability of carbon-based
coatings
a-C and a-C:H made by PMS and PECVD are generally
characterised by a reduced internal stress and improved
substrate adhesion when compared to ta-C ﬁlms. However,
and despite their excellent biocompatibility, these materials
still can’t fulﬁl all the requirements necessary for a permanent
and successful translation to real medical implants. These
coatings are particularly sensitive to wear and corrosion,
especially when deposited on metal substrates and exposed
to saline solutions or biological ﬂuids. It has been observed
that the prolonged exposure of the coatings to ﬂuids reduces
the interfacial strength, ultimately leading to delamination and
spallation at the coating / substrate interface [61,87,88].
Chandra et al. [88] proposed that failure of DLC coatings
after exposure to ﬂuids, such as water and phosphate buffered
saline (PBS), was related with the permeation and perforation
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coating surface.
A great amount of research has been undertaken to address
the issue of coating failure due to poor: (i) substrate adhesion
and (ii) wear and corrosion resistance. A potential solution for
the ﬁrst would be to increase the interfacial strength between
substrates and carbon-based coatings through the addition of
interlayers [87–93]. The deposition of silicon-based thin layers
between metallic substrates and DLC coatings, prepared by rf
—PECVD, can signiﬁcantly increase the adhesion strength of
DLC to stainless steel (SS) substrates. SiNx interlayers have
been reported as particularly effective for the enhancement of
both adhesion and coating corrosion resistance of samples
incubated in saline solution up to 2 years [87]. The deployment
of an a-Si:H to a-C:H graded interface (also prepared by
rf—PECVD) was shown to increase the adhesion strength and
corrosion resistance of DLC on Ti alloys [88]. The addition of
90 nm thick Si interlayers prior to DLC deposition on CoCrMo
substrates resulted in a substantial enhancement in the adhe-
sion strength when compared to non-interlayered samples [92].
Further enhancement of DLC adhesion strength to metallic
substrates can be fostered by creating a graded interface
between the metal surface and the carbon layer. Graded
metallic interfaces were previously reported and performed
on SS substrates prior to the deposition of carbon-based
plasma polymers (a-C:H ) using a low pressure PMS system
[94]. A SS target is bombarded by energetic argon atoms
coming from the plasma, which ultimately leads to the
sputtering of metallic ions from the target and their subsequent
deposition on the substrate surface. If a hydrocarbon precursor
(such as acetylene) is gradually added to the plasma during the
sputtering process, it is possible to create a metal-carbon
graded interface. This graded interface is characterised by an
increasing carbon to metal content from bottom to top with the
top layer being exclusively composed of DLC or a carbon-
based plasma polymer. The adhesion strength of DLC coatings
to SS substrates prepared with graded layers was reported to be
greater than 26 MPa. This value represents an improvement of
260% when compared to coating deposited directly on the
same substrates [94].
2.3. Biocompatibility
Biocompatible coatings for cardiovascular implants should
be inherently non-thrombogenic and able to recruit and
promote the proliferation of endothelium cells while inhibiting
the attachment and overgrowth of smooth muscle cell (SMC)
layers. They should fully integrate into the human vasculature
by prompting healing responses to prevent implant rejection
and severe immune responses post-implantation. Implant
hemocompatibility can be achieved by preventing the adsorp-
tion and further denaturation of undesirable blood proteins that
mediate the pathways of blood clot formation. The attachment,
on the coating surface, of bioactive molecules that could
prevent platelet adhesion and activation and that could be
capable of further inducing favourable local cellular responses
would represent a great advantage.Although plasma synthesised carbon-based coatings were
shown to retain good hemocompatibility in various in-vitro
essays, in-vivo investigations to access their capacity for
endothelialisation, SMC inhibition and hemocompatibility are
seldom reported. Good results of these coatings in the great
majority of such in-vitro tests were explained by the higher
afﬁnity of the surfaces to preferentially adsorb albumin over
ﬁbrinogen. However, in-vitro tests poorly simulate the harsh
conditions of the human vasculature such as the high ﬂow
regimes of blood in arteries. High ﬂow regimes can lead to
desorption of adsorbed or weakly attached proteins. For this
reason covalent immobilization is preferred over physical
adsorption. Recent advances [36] showed that PECVD pre-
pared carbon-based coatings with high concentrations of long-
lived unpaired electrons can be used for the covalent attach-
ment of various biomolecules in their bioactive form. These
advances could establish a new era of truly bio-functional and
-compatible cardiovascular implants.
2.3.1. Adsorption of blood proteins
The biocompatibility and particularly the hemocompatibility
of a blood-contacting surface are strongly affected by the
afﬁnity of the surface to adsorb speciﬁc blood proteins. The
time scale on which blood proteins interact with and are
adsorbed on a coating’s surface is several times smaller than
that of any of the interactions involving other blood compo-
nents. For this reason, local cellular response to a foreign body
implanted in a blood vessel will be in part governed by the
nature of the proteins adsorbed on its surface. For instance, it is
known that adsorbed ﬁbrinogen (Fib) enhances the adhesion
and activation of platelets [43], triggering the coagulation
pathway. Furthermore, Fib is also a fundamental element in the
coagulation cascade since it is cleaved into ﬁbrin to form an
irreversible thrombus. On the other hand, albumin can inhibit
the adhesion and activation of platelets, preventing the forma-
tion of a clot.
The mechanisms governing the adsorption of different blood
proteins on carbon-based surfaces are not yet fully understood.
The subject has driven increasing research in the last two
decades and although some advances have been achieved,
important questions remain unanswered. Difﬁculties arise in
determining exactly which physical and/or chemical properties
of the surfaces rule protein adsorption. Available data suggest
surface roughness and surface energy, hydrogen and nitrogen
fraction, sp3 content and electrical band-gap as possible
candidates. However, these properties are generally interlinked
and their decoupling is largely limited by the deposition
technique used to prepare the surfaces.
It has been suggested that the adsorption of blood proteins
on a DLC surface is related to the charge (electrons) transfer
between the proteins and the surface [56,95]. Protein adsorp-
tion and further denaturation occurs if the Fermi energy level
of the protein is such, that electrons from its valence band are
transferred to the conduction band of the coating material [95].
Therefore, hemocompatible coatings should be made with
electron energy band gaps greater than those of proteins that
are responsible for the formation of thrombus—such as
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hand, adsorption of albumin would be favourable as it can
inhibit the activation of platelets on the surface of the ﬁlm.
It has also been reported that surface roughness and
wettability may inﬂuence the adsorption of blood proteins
onto the surfaces [80,97–99]. Albumin for instance was
described to have greater afﬁnity for more hydrophilic and
rougher ta-C surfaces, made by ﬁltered arc deposition, when
compared to smoother and less hydrophilic a-C:H thin ﬁlms
prepared by plasma-enhanced chemical vapour deposition
(PECVD) [80]. However, different chemical compositions
(e.g. hydrogen content) and bonding conﬁgurations between
the different samples may have also inﬂuenced protein
adsorption. Using spectroscopic ellipsometry (ES) [97] sug-
gested that different a-C:H coatings made by plasma magne-
tron sputtering can adsorb human serum albumin (HSA) and
human ﬁbrinogen (Fib) differently. In this work the surface
concentration ratio (proportional to the thickness of the
adsorbed protein layer) HSA/Fib1 was higher for samples
prepared with ﬂoating potential whereas surfaces made using a
negative bias presented a ratio HSA/Fib0.4. Later the same
authors [85] showed that a-C:H coatings made under the same
conditions presented a different behaviour with respect to HSA
and Fib adsorption. The HSA/Fib thickness ratio was found to
increase on samples prepared with bias, which were identiﬁed
by AFM as being rougher. Berlind et al. [99] studied HSA
adsorption on different amorphous, graphitic and fullerene-like
surfaces also using spectroscopic ellipsometry. They found that
amorphous structures, i.e. with smoother surfaces, adsorbed
more HSA when compared with graphitic and fullerene-like
thin ﬁlms. However, the authors could not correlate a higher
HSA adsorption exclusively with the roughness of the thin
ﬁlms. This was because the different ﬁlms also presented
different chemical structure, wettability and water-binding
afﬁnities which are important parameters that also inﬂuence
protein adsorption. Available data suggests that blood protein
adsorption is a complex phenomenon and there is still no clear
consensus on its drivers. Additional investigations are there-
fore necessary to understand the basic phenomena of protein/
surface interactions and how different features in the surfaces
can regulate differential protein absorption.
2.3.2. Surface functionalisation with immobilised bioactive
molecules
Recent studies found that rf-PECVD carbon-containing plasma
polymers prepared with bias have the ability to covalently
immobilise proteins in their bioactive form [36,38]. Organic
precursor plasma discharges can be used to deposit hydrophilic
plasma activated radical-rich a-C:H-like coatings (PAC) if sufﬁ-
cient sample bias, usually up to 1 kV, is provided [100]. Here,
the ions formed in the plasma are accelerated with increased
energy provided by the high voltage bias towards the growing
carbonised ﬁlm on the substrate surface. Ion impact promotes the
formation of regions of carbon extended states such as π
conjugated sp2 carbon bonds with a high degree of cross-
linking. These regions contain stable unpaired electrons that can
move and diffuse towards the coating surface. Free-radicalcontent, measured by electron paramagnetic resonance spectro-
scopy, was found to be proportional to the bias voltage and
thickness of the deposited ﬁlm [94]. Colorimetric assays using
immobilised horseradish peroxidase catalase as a probe have been
employed to conﬁrm the capability of PAC coatings to retain the
bioactivity of the immobilised protein layer [38,45,101]. A variety
of polyamino acids have also been found to be covalently attached
to PAC surfaces via chemical bonding with the unpaired electrons
on the ﬁlm’s surface [36].
Metallic substrates such as stainless steel when coated with
PAC alone are signiﬁcantly more hemocompatible, a property
revealed by its ability to considerably reduce the formation of
human thrombus in different in-vitro assays. Blood compat-
ibility is an essential characteristic for biocompatible cardio-
vascular stents and although necessary, it does not address
endothelialisation and restenosis. A stable immobilization of
bioactive biomolecules on the coating surface could represent a
leap forward towards the true biofunctionalization of cardio-
vascular implants such as arterial stents. Plasma-made radical-
rich coatings for stents can be envisaged, immobilising the
appropriate biomolecule or biomolecule cocktails, to impart
appropriate local biological responses to achieve full vascular
integration of stents (see Fig. 1).
The advances discussed above suggest that chemical conjuga-
tion of proteins through the reactions of unpaired electrons with
protein amino acid side chains is possible while preventing protein
denaturation. It was shown that PAC surfaces could be used for
the immobilization of tropoelastin in a bioactive conformation on
ﬂat stainless steel substrates [37]. Tropoelastin, being a precursor
of elastin, is an important vascular protein since it participates in
the correct structuring and functionalization of the whole vascular
system. Elastin provides fundamental rheological properties to
blood vessels, facilitates endothelialisation and constitutes
(together with collagen) the sub-endothelia layer, the lamina,
interfacing the intima and the media. As an essential component of
the lamina, elastin ﬁbres play an important role in avoiding
inﬁltration of smooth muscle cells towards inner layers of the
blood vessel while promoting and regulating the growth and
proliferation of luminal endothelial cells to form a healthy
endothelium. Covalently immobilised tropoelastin and speciﬁc
domains of tropoelastin were shown to drastically enhance the
hemocompatibility of PAC coated SS substrates in in-vitro assays
using human whole blood [102]. Endothelial cell attachment and
proliferation were also improved when compared to uncoated
samples.
More recently, PAC surfaces functionalised with bioactive
plasmin revealed superior human blood compatibility and
endothelialisation [103] when compared to SS controls.
Plasmin is an enzyme, derived from plasminogen, present in
the blood that cleaves ﬁbrin clots in a process called
ﬁbrinolysis. When conjugated with PAC, plasmin is able to
prevent the formation and deposition of ﬁbrin complexes
reducing the probability of clot development. Hemocompat-
ibility and good in-vitro proliferation rates of endothelial cells
suggest that stents functionalised with PAC immobilised
plasmin could prevent early thrombogenicity while promoting
endothelialisation for stent vascular integration.
Fig. 1. Proactive biofunctionalization of coronary stents using plasma discharges in carbon-based atmospheres. The stent is electrically biased to accelerate plasma
positive ions towards the growing coating, creating therefore a radical-rich plasma activated coating (PAC). Biomolecules are then immobilized on the coating via
radical bonding and they maintain a bioactive conformation after immobilization. Following stent implantation, the immobilized biomolecules induce favourable
local cellular responses promoting endothelial cell migration, adhesion and proliferation on the implant surface to form a healthy endothelium. Smooth muscle cell
proliferation and platelet activation is inhibited, preventing neointimal hyperplasia and the formation of thrombi to achieve favourable integration of the implanted
stent in the host vasculature.
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were also recently studied for hemocompatibility, endothelializa-
tion and smooth muscle cell proliferation [104]. A low concentra-
tion of high density lipoproteins in the blood was previously
associated with restenosis and thrombosis after stent deployment
and coronary angioplasty. PAC was shown to covalently immo-
bilise constituents of HDL while retaining its bioactivity. Stainless
steel PAC coated substrates functionalised with HDL strikingly
reduced the formation of human blood clots in-vitro. Moreover,
HDL coated surfaces encouraged endothelialisation and prevented
the over-proliferation of smooth muscle cells.
3. Translation of carbon-based coatings to coronary stents
Signiﬁcant efforts have been made to develop biocompatible
coatings for metallic cardiovascular implants and especially for
coronary stents. Although plasma discharges are perceived as a
promising solution to fulﬁl this task, a great deal of research
still needs to be carried out. Despite the increasing volume of
investment and research, there is still no available plasma-
based coating technology for stents proved to successfully
address all the aspects of biocompatibility in humans.
3.1. Challenges
Stents are three-dimensional objects with wide-ranging dimen-
sions, aspect ratios, complex geometries and strut designs.
Consequently, coating uniformity using appropriate plasma dis-
charges such as low pressure PECVD or PMS is a non-trivial task.
One of the main challenges is to avoid edge and shadowing effects
on the stent struts caused either by adjacent struts or by the
electrical connections used to support the stent in the discharge. rf-
PECVD discharges can provide stable plasma media that uni-
formly surround ﬂat surfaces during the deposition process. Also,
when using sample biasing, ions are accelerated uniformly
towards the full length of ﬂat surfaces when a uniform sheath
lies between the plasma and the sample surface. However, theintricate design of a stent and the use of electrical and supporting
contacts give rise to the development of complex plasma sheaths
that are not totally conformal to the stents. For this reason a
thickness gradient in the coating across the stent outer surface is
usually hard to avoid. Moreover, while the outside struts are
directly coated and bombarded with energetic ions from the
surrounding reactive plasma, the inner struts are exposed only to
the poor plasma and less energetic ion ﬂux inside the stent.
Therefore, the physical and chemical properties of the coating are
generally spatially dependent. Coating thickness, for instance, is
usually thinner on the inside struts. Importantly, the bonding
conﬁguration has also been reported to be different in the outer
and inner struts with the latter showing lower sp3/sp2 ratios [105].
Strut shadowing is particularly accentuated when using PMS
discharges as the great majority of these platforms are built
with planar magnetrons providing only unidirectional sputter-
ing. When no rotation is applied to the stent, gradients in the
thickness of the coating are to be expected as thicker layers are
deposited on the struts facing the magnetron. An enhancement
of the coating uniformity could be achieved using, for instance,
hollow cathode magnetrons (HCM) instead of planar ones.
HCM discharges [106–108] use cylindrical targets that sur-
round the samples to be coated. When the plasma is generated
the sputtered material covers the outer layers of the samples
facing the target. In addition, rotation can be applied to
minimise shadowing of the inner struts. Using this technology
could, however, still face some possible drawbacks. Shadow-
ing would not be totally eliminated since a mechanical support
to hold and rotate the stent inside the magnetron would still be
required. Additionally, it is known that coating properties, such
as thickness, are strictly dependent on the aspect-ratio (radius
to length ratio) of the magnetron [108]. Therefore, custom-
made HCM reactors would need to be built to ﬁt speciﬁc stent
dimensions, a demand that could largely decrease the cost
efﬁciency and compromise the universality of the process.
Stent design imposes a further obstacle with regards to its
surface characterization. An accurate determination of the bulk
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chemical (elemental composition, atomic bonding conﬁgura-
tion, etc.) properties using the standard characterisation and
spectroscopic techniques is difﬁcult to achieve. The biocom-
patibility of coatings deposited on stents is even more
challenging to assess in-vitro since it is hard to reproduce
and quantify cellular attachment and proliferation on non-two-
dimensional ﬂat surfaces.
Stents are subjected to extreme radial and longitudinal
forces communicated by an expandable catheter balloon during
deployment. Localised plastic deformation follows stent
expansion and for this reason the coatings should be extremely
robust to avoid cracking and spallation in the areas subjected
to high strains. Fig. 2 shows examples of carbon-based coated
SS stents that underwent balloon expansion. The coatings were
prepared by PECVD using acetylene as a precursor gas.
Micro-sized cracking and delamination occurred in the regions
where strain was more accentuated which is shown by the
development of plastic deformation in the strut—Fig. 2a and b.
Although spallation was not propagated throughout the strut,
exposure of such coating to the blood stream could aggravate
delamination leading to further peeling. Fig. 2c–f show peeling
and spallation examples of similar coatings following crimp
and balloon expansion. Low adhesion strengths of the coatings
resulted in a generalized peeling and major areas of the
underlying stent material were exposed.
Given these reasons it is no surprise that the vast majority of the
investigations available in the literature are merely preliminary,
reporting the deposition and characterization of plasma-synthesised
coatings on ﬂat substrates. For instance, the adsorption of blood
proteins, the adhesion and activation of platelets and the attachment
and proliferation of smooth muscle cells and endothelial cells are
typically assessed on coatings deposited on Si-wafers and ﬂat
metallic samples. Also, correlations between: (i) plasma deposition
parameters, (ii) coating physical, chemical and mechanical proper-
ties and ultimately (iii) coating biocompatibility are also performed
in similar circumstances. However, one should expect that coatings
grown on ﬂat samples would perform differently from actual
coated stents in in-vitro and particularly in in-vivo. Only few works
addressed these issues but not to their full extent.
3.2. Plasma-assisted coated stents
Polyethylene glycol (PEG) conjugated DLC coatings on
nitinol ﬂat samples revealed superior in-vitro hemocompatibility
presenting higher albumin/ﬁbrinogen adsorption rates and
decreased platelet adhesion when compared with bare metal
and DLC surfaces [109]. However, PEG/DLC coated nitinol
stent performance in canine iliac arteries was substantially
inferior revealing more developed neointimal hyperplasia areas
compared to DLC stents and even to control non-coated nitinol
stents [110]. The authors associated restenosis with the accumu-
lation of a thick collagen layer formed due to over proliferation
of ﬁbroblasts on the PEG surface, a factor that had been
overlooked in the previous in-vitro assays.
Kim et al. [93] studied the mechanical properties of DLC
coatings deposited on self-expandable nitinol vascular stents usinga focused ion beam system and acetylene gas as a carbon
precursor. Interlayers of Si were also deposited by magnetron
sputtering between the stent surface and the DLC layer for
assessment of potential enhancement of the coating adhesion
strength. Stents were exposed to high stresses through a mechan-
ism of stent contraction and expansion. DLC coatings deposited
without Si interlayers were found not to withstand stress as
delamination and spallation occurred at the strut / coating inter-
face. Cracking and delamination was prevented when a-Si
interlayer thicker than 0.6 nm was used. Unfortunately, there is
no detailed information on the chemical, physical and biological
characteristics of these DLC coatings. Similar results were found
elsewhere [61] on PECVD prepared DLC coated stainless steel
stents. The addition of an a-Si:H interlayer substantially enhanced
the mechanical stability of the carbon coatings following stent
expansion. However, the adhesion of similar coatings to stainless
steel ﬂat substrates was signiﬁcantly compromised after 1 month
of incubation in bioﬂuids. Endothelial cell and platelet attachment
was also studied on DLC coatings deposited on Si substrates.
Superior endothelialisation and reduced platelet adhesion were
found for thermally annealed a-C:H ﬁlms doped with Si.
Unfortunately, these results were not conﬁrmed on stents prepared
in the same conditions.
PAC coated 316L SS stents have been tested for both
mechanical stability and in-vivo performance [34,111]. The inclu-
sion of nitrogen in acetylene/argon PECVD discharges provided
improvements in the mechanical properties by reducing the
compressive stress and in increasing the elasticity of the coatings.
Superior ability for tropoelastin covalent immobilization on 316L
ﬂat samples was observed for coatings prepared under such
conditions, which was congruent with an enhancement in endothe-
lialisation. PAC coated directly onto stents prepared in such
circumstances resisted delamination and spallation following a
balloon expansion with only nano-sized cracks emerging but
without exposing the underlying strut. Graded interfaces between
the metallic strut surface and PAC coatings can be made to further
enhance PAC mechanical stability in animal trials [34]. Although
PAC alone did not present signiﬁcant in-vivo improvements in
stent biocompatibility, further functionalization of PAC surfaces
with speciﬁc strongly bounded bioactive biomolecules could
overcome the limitations of current stent platforms.
4. Conclusions and future perspective
Carbon-based coatings, prepared either by plasma magne-
tron sputtering (PMS) or by plasma enhanced chemical vapour
deposition (PECVD), are among the most promising plasma-
based coatings for cardiovascular implants, particularly stents.
These are generally characterised by a reduced internal stress
and improved hemocompatibility. Recently, carbon-based
plasma polymers were reported to prevent the adverse response
to metallic substrates through linker-free immobilization of
bioactive molecules via free-radicals embedded in the coating.
The radicals present in the coatings, prepared by PECVD with
the aid of high voltage bias, allow for the covalent binding of
various types of proteins. Because the proteins maintain their
bioactivity, these coatings can regulate favourable cellular
Fig. 2. (a) SEM image of a balloon expanded 316L stainless steel (SS) stent coated with a carbon thin ﬁlm deposited by PECVD. Arrows indicate the areas of
aggravated plastic deformation. Strain accumulation in the superior region of the strut is indicated by the square; Scale bar denotes a length of 50 mm. (b) zoom of
ﬁgure (a) showing micro-cracking and delamination of the carbon coating due to strain accumulation during stent expansion; Scale bar denotes a length of 1 mm.
(c) As in ﬁgure (a) but now showing an example of coating peeling and spallation after balloon expansion due to inadequate coating adhesion strength. In this case,
the underlying metal strut is exposed; scale bar denotes 65 mm. (e) Generalised peeling of the coating following stent crimp and balloon expansion. Major areas of
the metal substrate are exposed in this example; scale bar denotes 15 mm. (f) Electron X-ray dispersive spectroscopy (EDS) mapping of ﬁgure (e) displaying a small
region where the oxidized a-CN:H coating remained adhered to SS stent; scale bar denotes a length of 3 mm.
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foreign object. The one-step and linker-free covalent immobi-
lization of a mixture of biomolecules capable of performing
different tasks independently would be extremely advanta-
geous, fostering novel and totally drug-free biocompatible
stent platforms.
Despite the advances, considerable improvements must be
made for a successful commercialisation of biocompatible coated
stents using plasma discharges. The majority of the publishedinvestigations in the ﬁeld are still very preliminary. Plasma-based
coatings are still frequently deposited and characterised on ﬂat
samples such as Si wafers and/or metallic ﬂat sheets. The
complex 3D geometry of a stent sets an additional challenge.
Uniform coatings are hard to achieve due to shadowing effects
either caused by the stent itself or by the electrical connections or
mounts used to hold the stent in the plasma chamber. Further-
more, it is also expected that the physical, chemical and
tribological properties of coatings deposited on ﬂat samples
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Fig. 3. A proposed strategy for the development of a controllable and stable process for the production of biocompatible coatings for cardiovascular stents using
plasma discharges (red arrows indicate the ﬂow of information). This strategy involves the development of plasma hybrid simulation tools ﬁtted with appropriate
models capable of describing the main physical quantities of the plasma, plasma chemistry and transport and plasma interaction with surfaces during the deposition.
Model results need to be conﬁrmed and validated with experimental measurements obtained by means of plasma diagnostics. Ultimately, such models would be
used for a complete scaling and optimization of the plasma reactor. Coated stents must be tested for mechanical stability, wear and corrosion resistance. Also, the
physical and chemical properties of such coatings should be determined using appropriate characterization techniques. Coating functionalization through stable
covalent immobilization of bioactive molecules is then performed. These molecules (or cocktail of molecules) should be chosen to address thrombogenicity,
endothelialisation and restenosis and their efﬁcacy should be tested in in-vivo, ex-vivo and in-vitro. Iterative feedback between plasma modelling, plasma
diagnostics, coating characterization (before and after functionalization) and coating biological performance offer a strategy to identify the correct window of plasma
parameters for the production of coatings with the necessary mechanical, physical, chemical and biocompatible properties.
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samples. Therefore, further in-vitro and in-vivo essays are
certainly needed to access plasma-coated stent performance.
Additionally, a full understanding of the fundamental
processes governing the plasma medium during the deposition
process is far from being achieved. The use of reactive
mixtures containing hydrocarbon precursors gives rise to
complex plasma chemistries. The use of sample biasing, the
three-dimensional geometry of the samples and the addition of
reactive dopants such as nitrogen or hydrogen representadditional challenges. The main kinetic mechanisms and the
physical quantities to describe such discharges are not yet
clear, demanding therefore the development of advanced
plasma modelling tools capable of describing the complexity
of the plasma medium. Principally, a connection between the
process parameters and their effects on the ﬁnal coating
properties are not yet elucidated. Not even for simplest gaseous
mixtures. The mechanical stability of the coating, its capability
to be further functionalised and its biocompatibility needs to be
thoroughly investigated as a function of changes in the
M. Santos et al. / Biosurface and Biotribology 1 (2015) 146–160 157physical and chemical properties induced by varying appro-
priate process parameters. Combinations of plasma discharge
simulation tools, plasma diagnostics and coating characteriza-
tion techniques could be used to identify the relevant window
of plasma parameters for a reproducible and stable process (see
Fig. 3) and ultimately offer feedback control strategies. Such
an interdisciplinary endeavour will only be possible through
combined efforts of scientiﬁc communities in plasma physics,
materials engineering, biology and medicine.
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